A17 Inhibition of RUVBL1/2 ATPase Activity Drives Immune Infiltration and Radiosensitizes Non-Small Cell Lung Cancer

Patient-derived NSCLC lines were treated with clinically relevant chemotherapies, targeted inhibitors, or radiation in combination with a highly specific RUVBL1/2 inhibitor or its enantiomer control and cell viability was measured. RUVBL1/2 inhibition significantly enhanced the killing of NSCLC following radiation, but not chemotherapy or other targeted agents. This enhancement was specific to NSCLC, not normal bronchial epithelial cells, and...